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Abstract. – OBJECTIVE: Critical limb is-
chemia (CLI) patients have poor long-term prog-
nosis. We showed that iloprost improves out-
comes (major amputation and survival) up a 5-
year follow-up, but it is not known if in this
length of time the survival curves, of clinical re-
sponders and non-responders, differ.
PATIENTS AND METHODS: A retrospective
study enrolling 102 consecutive patients be-
tween 2004-2008, with clinical and instrumental
(ultrasound, angiography, transcutaneous ten-
siometry of oxygen TcpO2 and carbon dioxide
TcpCO2 in the affected and contralateral limbs)
diagnosis of critical ischemia. All patients re-
ceived the best medical therapy. Iloprost was ad-
ministered (0.5-2 ng/kg/min 6 hours/day for 2-4
weeks) in all patients initially considered unsuit-
able for revascularization, repeating it regularly
in time every six-twelve months in the case of
positive response. The minimum expected fol-
low-up was 4 years.
RESULTS: 71.5% of patients were treated with
iloprost and the responder rate was 71.2%.
Most of the patients were regularly retreated
with repeated cycles. Initial median supine Tcp-
CO2 in symptomatic limb was higher in untreat-
ed patients than those treated (58 vs. 49 mmHg;
p < 0.05) and in non-responders compared to
responders (60 vs. 49 mmHg; p < 0.05). TcpCO2
directly and significantly correlated with the
highest risk of mortality and seems to repre-
sent a new accurate prognostic criterion of un-
favourable short and long-term response to
prostanoid. In iloprost group, major amputa-
tions were significantly reduced. Revasculariza-
tion was significantly higher in non-responders
(57.1% vs. 11.5%; p < 0.05). There was a signifi-
cantly higher prevalence of subsequent my-
ocardial infarction in the non-iloprost group
(27.6% vs. 9.6%; p < 0.05).
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The survival rate of non-responders was high-
er than untreated up until the second year
(76.2% vs. 62%; p < 0.05). At 4 years we found
higher survival in patients treated with iloprost
(64.3% vs. 41% in untreated; p < 0.05) and in re-
sponders (75% vs. 38.1% in non-responders; p <
0.05).
CONCLUSIONS: Our results confirm the
favourable role of iloprost on the long-term out-
come in patients with CLI. In particular, the maxi-
mum benefit is obtained in responder patients
treated with multiple cycles of infusion.
Key Words:
Critical limb ischemia, Iloprost, Prostanoid, Respon-
der rate, Transcutaneous tensiometry.
Introduction
Critical limb ischemia (CLI) is a major health-
care issue, involving approximately 500-1000
people per million of the population and charac-
terized by a poor long-term prognosis. At one
year from diagnosis, when untreated, major limb
amputation is required in 30% of patients, and
overall mortality is 25%1,2. The treatment goals
are, therefore, not only to relieve ischemic pain
and heal ulcers, but also prevent limb loss, im-
prove patient function and quality of life, and,
primarily, prolong survival. The most consolidat-
ed approaches consist of surgical or endovascular
revascularization as a first choice, but many CLI
patients are often not eligible for such proce-
dures: compared to the past patients tend to be
elder, present greater comorbidities and severe
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of their long-term survival or subsequent proce-
dures, such as major and minor amputations and
surgical or endovascular treatments.
Patients and Methods
Case-control, retrospective study performed in
January 2013, conducted following the Declaration
of Helsinki and current ethical standards. The
study included 102 CLI patients consecutively ad-
mitted to different medical and surgical wards of
the University Hospital of Pisa, Italy, between
2004-2008. The only inclusion criterion was the
clinical and instrumental diagnosis of critical is-
chemia of the lower limbs. Ultrasound examina-
tions and/or angiography of the lower extremities
were performed in all patients to confirm the diag-
nosis. The instrumental evaluation included tran-
scutaneous tensiometry of oxygen (TcpO2) and
carbon dioxide (TcpCO2) in the affected and con-
tralateral limbs, in supine and dependent positions,
performed at the first visit and later at each assess-
ment. Every patient was evaluated by a multidisci-
plinary team (Internist, Angiologist, Interventional
Radiologist, Vascular Surgeon) to choose an ade-
quate approach. All patients were treated with the
best systemic medical therapy, in particular with
anti-aggregants, statins and ACE-inhibitors or ARB
(angiotensin receptor blockers). Iloprost was ad-
ministered in all patients initially considered un-
suitable for revascularization for high operative
risk and /or significant comorbidities. The adminis-
tration regimen was 0.5-2 ng/kg/min for 6
hours/day for 2-4 weeks, repeating it regularly in
time every six-twelve months in the case of posi-
tive clinical and instrumental response. The re-
sponse to iloprost was assessed one month after the
last administration. Response criteria were consid-
ered: for stage III patients the complete disappear-
ance of ischemic pain and regression to the stage of
claudication; for stage IV patients the total disap-
pearance of lower limbs ischemic pain, the com-
plete healing of ulcers or a reduction equal to or
greater than 50% of initial diameter and the demar-
cation of necrosis. After that we considered a med-
ical assessment of global response, and we inte-
grate our clinical judgment with the significant im-
provement of transcutaneous tensiometry measure-
ments. In the years following diagnosis, all patients
underwent repeated clinical and instrumental ex-
aminations. The data used in this study were ob-
tained from medical records of patients. All pa-
tients and/or their families (and possibly general
general impairment. For the above reasons, in
these CLI patients vascular rehabilitation may
present further technical problems.
Patients who have a viable limb in whom
revascularization procedures are not possible, or
carry a poor chance of success or have previously
failed, may be treated with prostanoids, particu-
larly when the alternative is amputation. Among
prostanoids, iloprost, a synthetic prostacyclin
analogue, has the best evidence for positively in-
fluencing overall survival of patients and limb
loss1-6. A recent Cochrane review7 stated that
prostanoids seem to have efficacy regarding rest-
pain relief and ulcer healing, and iloprost also
shows favorable results in the reduction of major
amputations. The latest guidelines underline that
prostanoid treatment should be considered not
only as a first-choice therapy in the alternative to
peripheral vascular rehabitation8,9, but also as
complementary/adjuvant therapy in candidates
for surgical or endovascular revascularization10,11.
Despite many positive results and statements
regarding rest-pain relief, ulcer healing and am-
putations reduction, until now there was no con-
clusive evidence based data on the long-term ef-
fectiveness and safety of different prostanoids in
patients with CLI7,12. Furthermore, the follow-up
of patients treated with iloprost was quite brief
(6-24 months)5,6,13,14. Recently we described15 a
population of 181 consecutive CLI patients, 46%
of whom treated with intravenous iloprost: com-
pared to untreated patients they showed better
outcomes in terms of significant reduction of ma-
jor amputation (6% vs. 21%) and subsequent vas-
cular surgery (4% vs. 32%) and significant im-
provement of survival rates (69% vs. 47%) at a 5
year follow-up. Our work was the first to assess
the effect of iloprost on survival rate over such a
long time, but we have not further distinguished
the survival curves of CLI patients treated with
iloprost between those clinical responders and
non-responders to treatment.
It has been established that at least in a period
of 6 months responder CLI patients have signifi-
cantly fewer major amputations and mortality
rates compared to non-responders16, but no data
is available over a longer period. The aim of this
study is to evaluate, in another large population
of CLI patients treated with several cycles of in-
travenous iloprost, in addition to the best medical
treatment, if the favorable results obtained in our
previous work are confirmed in this more recent
research and if there are any different outcomes
between responders and non-responders, in terms
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Overall population Non-Iloprost Iloprost Significant
No. = 102 No. = 29 No. = 73 differences
Age (mean ± SD; years) 75 ± 8 74.2 ± 6.8 75.9 ± 8.9
Males 43% (n = 44) 41.3% (n = 12) 43.8% (n = 32)
Diabetes mellitus 53% (n = 54) 72% (n = 21) 45% (n = 33) p < 0.05
Hypercolesterolemia 62% (n = 63) 48.2% (n = 14) 67% (n = 49)
Hypertension 81% (n = 83) 79% (n = 23) 82% (n = 60)
Smokers (active) 7% (n = 7) 14% (n = 4) 4% (n = 3) p < 0.05
Smokers (previous) 51% (n = 52) 62% (n = 18) 47% (n = 34)
Previous surgery/PTA 29% (n = 30) 34% (n = 10) 27% (n = 20)
Previous controlateral amputation 4% (n = 4) 7% (n = 2) 3% (n = 2)
Stage Leriche-Fontaine III 21% (n = 21) 28% (n = 8) 18% (n = 13)
Stage Leriche-Fontaine IV 79% (n = 81) 72% (n = 21) 82% (n = 60)
Coronary artery disease 53% (n = 54) 48% (n = 18) 55% (n = 40)
Previous myocardial infarction 28% (n = 29) 31% (n = 9) 27% (n = 20)
Atrial fibrillation 25% (n = 25) 17% (n = 5) 27% (n = 20)
COPD 25% (n = 26) 21% (n = 6) 30% (n = 22)
Previous stroke 12% (n = 12) 7% (n = 2) 14% (n = 10)
TcpO2 median in symptomatic limb
Supine mmHg (range) 3 (0-30) 2 (0-30) 3 (0-30)
Dependent mmHg (range) 35 (0-60) 25 (1-60) 35 (0-59)
TcpCO2 median in symptomatic limb
Supine mmHg (range) 50 (37-180) 58 (40-180) 49 (36-140) p < 0.05
Dependent mmHg (range) 40 (35-80) 40 (35-80) 39 (35-70)
Iloprost treatment
1 cycle Not applicable Not applicable 47.9% (n = 35)
2-3 cycles 24.7% (n = 18)
> 3 cycles 27.4% (n = 20)
Survival
1 year 86.2% (n = 88) 76% (n = 22) 90.4% (n = 66)
2 years 77.4% (n = 79) 62% (n = 18) 83.5% (n = 61)
3 years 68.6% (n = 70) 52% (n = 15) 75.3% (n = 55)
4 years 57.8% (n = 59) 41% (n = 12) 64.3% (n = 47) p < 0.05
Subsequent procedures
Major amputations 4.9% (n = 5) 13.8% (n = 4) 1.4% (n = 1) p < 0.05
Minor amputation 11.7% (n = 12) 13.8% (n = 4) 10.9% (n = 8)
Vascular surgery 24.5% (n = 25) 24.1% (n = 7) 24.6% (n = 18)
Table I. Clinical characteristics and outcomes of CLI population.
PTA: percutaneous transluminal angioplasty; SD: standard deviation; TcpO2: transcutaneous tissue oxygen tension; TcpCO2:
transcutaneous tissue carbon dioxide tension; COPD: chronic obstructive pulmonary disease.
practitioners) were contacted with an invitation for
patients to undergo a new outpatient control when
the visit had been previously programmed as usual
in our clinics. In case of death, certificates were
collected. Collected data included demographic
and clinical characteristics, concomitant and previ-
ous diseases, major and minor amputations, com-
plications of CLI, mortality rates, causes of death,
and administered medical treatments.
Statistical Analysis
The differences between categorical and contin-
uous variables after logarithmic transformation for
non-normally distributed data were calculated us-
ing the χ2-square test and one-way ANOVA. The
statistical associations were calculated using multi-
variate logistic regression using the status in life
and other outcomes as a binary variable (coded as
0 and 1). Odds ratio (95% CI) was used for relative
risk estimate. Descriptive statistics were represent-
ed as the mean ± standard deviation (SD) or medi-
an for data in non-normal distribution. Statistical
significance was considered at p-values < 0.05.
Results
Characteristics of Patients’ Population
Table I shows baseline demographic and clini-
cal characteristics and outcomes in the treated
and untreated with iloprost groups.
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The minimum duration of follow-up for the
overall population was 4 years, with a median of
5.2 years.
More than two-thirds (71.5%) of CLI patients
were treated with iloprost, while the remaining
underwent percutaneous angioplasty (16.6%),
peripheral bypass (4.9%), chronic spinal cord
stimulation (3%) or gene therapy or vasoactive
infusion (4%). The majority (79%) was in stage
IV Leriche-Fontaine and 29% had already had
previous surgery or PTA.
Regarding drug therapy, at the first visit, 67.6%
were taking antiplatelet therapy (in the non-ilo-
prost group the percentage was even higher:
72.4%), and 63.7% were taking anticoagulants
(heparin, warfarin), so almost all patients were in
anti-thrombotic therapy. 49% were using ACE-in-
hibitors and 23.5% ARB. Little more than half
(57.8%) was taking statins, without significant dif-
ferences between the treated and untreated groups.
Iloprost Treatment
The majority of patients were treated with ilo-
prost (71.5%): the load of serious comorbidities
(such as coronary artery disease, previous myocar-
dial infarction, atrial fibrillation, COPD, previous
stroke) was similar between the two groups.
There was a significantly higher prevalence of
subsequent myocardial infarction in the non-ilo-
prost group (27.6% vs. 9.6%; p < 0.05).
In iloprost group the responder’s rate was
71.2%: subsequently, the majority was regularly
retreated with further administrations: 2-3 cycles
in 26.9% of cases and 4 cycles or more in other
38.4%, while the great majority (81%) of non-re-
sponders to a first apparently clinically ineffec-
tive cycle of iloprost discontinued treatment.
Table II shows the baseline demographic and
clinical characteristics and the outcomes observed
in patients treated with iloprost, subdivided into
responders and non-responders to treatment.
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Iloprost responders Iloprost non-responders Significant
No. = 52 No. = 21 differences
Age (mean ± SD; years) 76.2 ± 9.3 75.2 ± 8.1
Males 36.5% (n = 19) 61.9% (n = 13) p < 0.05
Diabetes mellitus 50% (n = 26) 33.3% (n = 7)
Hypercolesterolemia 67.3% (n = 35) 66.6% (n = 14)
Hypertension 86.5% (n = 45) 71.4% (n = 15)
Smokers (active) 1.9% (n = 1) 9.5% (n = 2) p < 0.05
Smokers (previous) 36.5% (n = 19) 71.4% (n = 15) p < 0.05
Previous surgery/PTA 32.7% (n = 17) 14.2% (n = 3)
Previous controlateral amputation 1.9% (n = 1) 4.7% (n = 1)
Stage Leriche-Fontaine III 19.2% (n = 10) 14.2% (n = 3)
Stage Leriche-Fontaine IV 80.7% (n = 42) 85.7% (n = 18)
TcpO2 median in symptomatic limb
Supine mmHg (range) 3 (0-30) 2 (0-10)
Dependent mmHg (range) 40 (0-59) 30 (5-52)
TcpCO2 median in symptomatic limb
Supine mmHg (range) 49 (36-140) 60 (47-110) p < 0.05
Dependent mmHg (range) 40 (35-55) 40 (37-70)
Iloprost treatment
1 cycle 34.6% (n = 18) 81% (n = 17)
2-3 cycles 26.9% (n = 14) 19% (n = 4)
> 3 cycles 38.4% (n = 20) 0% (n = 0)
Survival
1 year 94.2% (n = 49) 81% (n = 17)
2 years 86.5% (n = 45) 76.2% (n = 16)
3 years 82.7% (n = 43) 57.1% (n = 12)
4 years 75% (n = 39) 38.1% (n = 8) p < 0.05
Subsequent procedures
Major amputations 0% (n = 0) 4.7% (n = 1)
Minor amputation 9.6% (n = 5) 14.3% (n = 3)
Vascular surgery 11.5% (n = 6) 57.1% (n = 12) p < 0.05
Table II. Clinical characteristics and outcomes in responders and non-responders to iloprost.
PTA: percutaneous transluminal angioplasty; SD: standard deviation; TcpO2: transcutaneous tissue oxygen tension; TcpCO2:
transcutaneous tissue carbon dioxide tension.
Survival
Figure 1 shows the survival curves of overall
population and of patients treated and not treated
with iloprost, while Figure 2 shows the further par-
tition of treated in responders and non-responders.
The survival rate of overall population at 1, 2,
3 and 4 years was, respectively, 86.2%, 77.4%,
68.6%, 57.8%.
At the fourth year of follow-up, the group of
patients treated with iloprost showed a signifi-
cantly better survival rate than those untreated
(64.3% vs. 41%; p < 0.05), and in responders sur-
vival was further significantly increased com-
pared to non-responders (75% vs. 38.1%; p <
0.05).
The survival rate of non-responders patients
was higher than that of untreated up until the sec-
ond year of follow-up (76.2% vs. 62%; p < 0.05).
Procedures
All procedures, when necessary, were per-
formed in the first 13 months from the initial ob-
servation of patients.
In the iloprost group, the rate of major ampu-
tations was only 1.4% (the only patient that un-
derwent amputation had been considered non-re-
sponder), significantly less than in the non-ilo-
prost group (13.8%) (p < 0.05).
No significant differences were observed for
the subsequent surgical revascularization be-
tween the iloprost and non-iloprost groups, but
the difference was significantly higher in the
non-responder group compared to responders
(57.1% vs. 11.5%; p < 0.05).
Transcutaneous Microcirculatory
Measurements
Regarding the transcutaneous microcirculatory
parameters initially obtained at symptomatic foot
in patients treated or not with iloprost, we
showed an overall marked microcirculatory
TCpO2 impairment expressed by very low
oximeter values (median supine TCpO2: 3 mmHg
vs. 2 mmHg, respectively) without significant
differences found between the two subgroups
(Table I).
Vice versa, the values of median supine Tcp-
CO2 in the symptomatic limb in the subgroup of
patients untreated with iloprost was significantly
higher than those treated (58 vs. 49 mmHg; p <
0.05).
Also, the comparison of microcirculatory pa-
rameters at the symptomatic limb between re-
sponders and non-responders patients showed no
significant differences regarding supine and de-
pendent oximetry, while we found significantly
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Figure 1. Survival curves in patients treated vs. untreated
with iloprost.
Figure 2. Survival curves in patients treated with iloprost:
responders vs. non-responders.
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more severe supine TcpCO2 values in non-re-
sponders vs. responders (60 vs. 49 mmHg, re-
spectively; p < 0.05) (Table II).
Finally, we found a significant correlation be-
tween the values of median supine TcpCO2 at the
forefoot of symptomatic limb and overall mortal-
ity of CLI patients, both in patients treated and
untreated with iloprost, and in the responders and
non responders groups (Figure 3).
Elevated values of supine TCpCO2 at sympto-
matic limb are therefore directly and significant-
ly correlated with higher risk of mortality.
Discussion
The majority of patients in our series, differ-
ently from the indications of the present pub-
lished guidelines1,3,17, were subjected in the first
instance to conservative medical therapy with
iloprost rather than revascularization. This ap-
proach was the result of a careful interdiscipli-
nary decision and was influenced not only by the
eventual surgical and/or endovascular feasibility,
but also by the consideration of the age of our
cases (mean 75 years; 33/102 ultra-octogenari-
ans) and precarious general conditions due to se-
vere comorbidities. Indeed, Biancari et al18
showed that the most important criteria to predict
30-day post-operative outcomes (mortality and
amputations) after infra-inguinal revasculariza-
tion were represented by the presence of gan-
grene, diabetes mellitus, coronary artery disease
and urgent operation, that are aspects strictly re-
lated to the complexity and comorbidities of CLI
patients. In our series we found a significant
presence of above-mentioned conditions: 79% of
our patients presented with ulcers or gangrene,
53% were diabetics and 53% had coronary artery
disease. Furthermore, some authors19 recommend
an algorithm in which the medical and wound
therapy alone may be a viable option for CLI pa-
tients with stable and uncomplicated tissue loss
and poor surgical candidates (for age > 75 years
or significant coronary artery disease or several
chronic kidney diseases). For all these reasons
we have preferred a conservative medical treat-
ment with iloprost in most of our CLI patients.
The prevalence of severe comorbidities result-
ed particularly relevant in patients treated with
iloprost, so the favorable effect on survival curve
observed in this group cannot have been positive-
ly influenced by a lower disease burden of pa-
tients themselves. After that, the optimal medical
therapy, such as antiplatelet, was equally repre-
sented both in groups treated and untreated with
iloprost.
The most favorable survival curves emerged in
patients treated with iloprost, that represent the
majority of our case series, and, among these, in
responders, once again representing the maxi-
mum part of the treated ones. A similar pattern
was described for major amputations.
One explanation for the significantly worse
prognosis in term of long-term survival found in
non-responders might be attributed to the lower
use of repeated cycles with iloprost, which may
have an effect on systemic protection from global
cardiovascular risk and overall survival15. Our da-
ta clearly show that survival of non-responder pa-
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Figure 3. Supine TcpCO2 at symptomatic limb and risk of death.
tients was better than that of untreated ones until
the second year of follow-up, so the concept and
criteria of non-response should perhaps be re-
vised. Patients initially labeled clinically as non-
responders should be treated with repeated cycles
of iloprost since it is possible to observe a posi-
tive clinical response to a repeated cycle after a
previous clinically ineffective one. The response
to iloprost must be measured on long-term out-
come, especially the survival, as we have recent-
ly demonstrated15 and as recent experiences on
effects of statins on overall survival of CLI pa-
tients have shown20.
After that we have found a significantly higher
prevalence of myocardial infarction in patients
untreated with iloprost (27.6% vs. 9.6%; p <
0.05), suggesting a global protection from major
vascular events provided by iloprost treatment
and thus justifying in part the reason for the re-
duction of mortality that we have observed.
Therefore, we can state that repeated cycles of
iloprost can be an appropriate response to the as-
sertion of Varu et al19 for which “these high-risk
patients are victims to the limitations of surgical
and medical management and the potential for
increased morbidity”.
In a previous study21 we showed that the mi-
crocirculatory worsening measurements repre-
sented by lower oxygen values and higher carbon
dioxide parameters are the prognostic indexes for
risk of limb loss with highest sensibility. High
values of supine TcpCO2 in symptomatic limb
are correlate with local metabolic acidosis, and
this work shows that they are significantly asso-
ciated with diminished response to iloprost. So,
they could be proposed as new accurate prognos-
tic criteria of unfavorable response to treatment.
Up to now we only knew that no predictive crite-
rion of long-term results could be established,
except initial clinical severity and clinical change
evaluated one month after treatment22.
It should be noted that the supine TcpCO2 in
symptomatic limb was significantly higher both
in patients untreated with iloprost and in non-re-
sponders, and in CLI patients represents not only
the most sensible prognostic factor for limb loss
(that notoriously correlates with survival) but al-
so directly correlates with mortality. From all
this, it is clear the need to diagnose and treat crit-
ical limb ischemia pharmacologically early be-
fore microcirculatory damage becomes irre-
versible.
Finally, we did not observe any differences in
rates of subsequent surgical revascularization be-
tween the iloprost and non-iloprost groups, as-
pect that is in line with our thinking that the two
strategies are complementary and not alternative
to each other, while the difference was significant
in the non-responder group compared to respon-
der, due to the extreme attempt of surgical ap-
proach for the extremely high risk of limb loss in
non-responder patients.
Our clinical management of CLI patients re-
flects our way of thinking and approaching this
condition, further stressing the paradigm of not
immediately revascularizable critical is-
chemia10,11 and the necessity of a continuous
clinical reassessment of patients in his complex-
ity. It testifies as iloprost can no longer be con-
sidered as a therapy reserved only for patients
unsuitable for revascularization and it should be
the frontline of treatment. For many patients, in
particular those seriously ill, we can initially
wait for and reserve the surgery at a later time,
for patients repeatedly non-responders to con-
servative medical therapy with iloprost; there-
after the assessment of TcpO2 and TcpCO2 at
symptomatic limb can improve our decision-
making process.
Conclusions
Iloprost in CLI patients is not an alternative to
peripheral revascularization s and should no
longer be considered appropriate only for unre-
constructable patients, but since it is effective for
relieving pain and healing tissue loss, improves
post-revascularization outcomes and quality of
life and, moreover, is the only treatment with
demonstrated positive effect on long-term sur-
vival, should be proposed to all patients affected
by severe ischemic disease of lower limbs.
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